Daniele Baiz
Daniele Baiz has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Anabel Flores
Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, North Carolina
5 shared publications - Ashok Pullikuth
Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, North Carolina
5 shared publications Kyle C. Nelson
5 shared publicationsSazzad Hassan
5 shared publicationsSinan Zhu
5 shared publications- Urs von Holzen
Department of Surgery, University Hospital Basel, Basel, Switzerland; Harper Cancer Research Institute, Indiana University School of Medicine South Bend, South Bend, IN, United States; Goshen Center for Cancer Care, Goshen, IN, United States
5 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from β2-adrenoreceptor Signaling Increases Therapy Resistance in Prostate Cancer by Upregulating MCL1
There is accumulating evidence that continuous activation of the sympathetic nervous system due to psychosocial stress increases resistance to therapy and accelerates tumor growth via β2-adrenoreceptor signaling (ADRB2). However, the effector mechanisms appear to be specific to tumor type. Here we show that activation of ADRB2 by epinephrine, increased in response to immobilization stress, delays the loss of MCL1 apoptosis regulator (MCL1) protein expression induced by cytotoxic drugs in prostate cancer cells; and thus, increases resistance of prostate cancer xenografts to cytotoxic therapies. The effect of epinephrine on MCL1 protein depended on protein kinase A (PKA) activity, but was independent from androgen receptor expression. Furthermore, elevated blood epinephrine levels correlated positively with an increased MCL1 protein expression in human prostate biopsies. In summary, we demonstrate that stress triggers an androgen-independent antiapoptotic signaling via the ADRB2/PKA/MCL1 pathway in prostate cancer cells.Implications:Presented results justify clinical studies of ADRB2 blockers as therapeutics and of MCL1 protein expression as potential biomarker predicting efficacy of apoptosis-targeting drugs in prostate cancer.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from β2-adrenoreceptor Signaling Increases Therapy Resistance in Prostate Cancer by Upregulating MCL1
There is accumulating evidence that continuous activation of the sympathetic nervous system due to psychosocial stress increases resistance to therapy and accelerates tumor growth via β2-adrenoreceptor signaling (ADRB2). However, the effector mechanisms appear to be specific to tumor type. Here we show that activation of ADRB2 by epinephrine, increased in response to immobilization stress, delays the loss of MCL1 apoptosis regulator (MCL1) protein expression induced by cytotoxic drugs in prostate cancer cells; and thus, increases resistance of prostate cancer xenografts to cytotoxic therapies. The effect of epinephrine on MCL1 protein depended on protein kinase A (PKA) activity, but was independent from androgen receptor expression. Furthermore, elevated blood epinephrine levels correlated positively with an increased MCL1 protein expression in human prostate biopsies. In summary, we demonstrate that stress triggers an androgen-independent antiapoptotic signaling via the ADRB2/PKA/MCL1 pathway in prostate cancer cells.Implications:Presented results justify clinical studies of ADRB2 blockers as therapeutics and of MCL1 protein expression as potential biomarker predicting efficacy of apoptosis-targeting drugs in prostate cancer.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from β2-adrenoreceptor Signaling Increases Therapy Resistance in Prostate Cancer by Upregulating MCL1
There is accumulating evidence that continuous activation of the sympathetic nervous system due to psychosocial stress increases resistance to therapy and accelerates tumor growth via β2-adrenoreceptor signaling (ADRB2). However, the effector mechanisms appear to be specific to tumor type. Here we show that activation of ADRB2 by epinephrine, increased in response to immobilization stress, delays the loss of MCL1 apoptosis regulator (MCL1) protein expression induced by cytotoxic drugs in prostate cancer cells; and thus, increases resistance of prostate cancer xenografts to cytotoxic therapies. The effect of epinephrine on MCL1 protein depended on protein kinase A (PKA) activity, but was independent from androgen receptor expression. Furthermore, elevated blood epinephrine levels correlated positively with an increased MCL1 protein expression in human prostate biopsies. In summary, we demonstrate that stress triggers an androgen-independent antiapoptotic signaling via the ADRB2/PKA/MCL1 pathway in prostate cancer cells.Implications:Presented results justify clinical studies of ADRB2 blockers as therapeutics and of MCL1 protein expression as potential biomarker predicting efficacy of apoptosis-targeting drugs in prostate cancer.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from β2-adrenoreceptor Signaling Increases Therapy Resistance in Prostate Cancer by Upregulating MCL1
There is accumulating evidence that continuous activation of the sympathetic nervous system due to psychosocial stress increases resistance to therapy and accelerates tumor growth via β2-adrenoreceptor signaling (ADRB2). However, the effector mechanisms appear to be specific to tumor type. Here we show that activation of ADRB2 by epinephrine, increased in response to immobilization stress, delays the loss of MCL1 apoptosis regulator (MCL1) protein expression induced by cytotoxic drugs in prostate cancer cells; and thus, increases resistance of prostate cancer xenografts to cytotoxic therapies. The effect of epinephrine on MCL1 protein depended on protein kinase A (PKA) activity, but was independent from androgen receptor expression. Furthermore, elevated blood epinephrine levels correlated positively with an increased MCL1 protein expression in human prostate biopsies. In summary, we demonstrate that stress triggers an androgen-independent antiapoptotic signaling via the ADRB2/PKA/MCL1 pathway in prostate cancer cells.Implications:Presented results justify clinical studies of ADRB2 blockers as therapeutics and of MCL1 protein expression as potential biomarker predicting efficacy of apoptosis-targeting drugs in prostate cancer.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-5 from β2-adrenoreceptor Signaling Increases Therapy Resistance in Prostate Cancer by Upregulating MCL1
S1. Epinephrine inhibits apoptosis by upregulatingMCL1in prostate cancer cells. S2.Epinephrine upregulates MCL1via the ADRB2/PKA pathway S3.C4-2shMCL1 cells with inducible expression of shRNAtargeting MCL1. S4. Effects of chemotherapy drugs on MCL1 expression in prostate cancer cells. S5. The loss of MCL1 expression in cells treated with chemotherapeuticdrugsis restored via ADRB2/PKA signaling.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-5 from β2-adrenoreceptor Signaling Increases Therapy Resistance in Prostate Cancer by Upregulating MCL1
S1. Epinephrine inhibits apoptosis by upregulatingMCL1in prostate cancer cells. S2.Epinephrine upregulates MCL1via the ADRB2/PKA pathway S3.C4-2shMCL1 cells with inducible expression of shRNAtargeting MCL1. S4. Effects of chemotherapy drugs on MCL1 expression in prostate cancer cells. S5. The loss of MCL1 expression in cells treated with chemotherapeuticdrugsis restored via ADRB2/PKA signaling.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-5 from β2-adrenoreceptor Signaling Increases Therapy Resistance in Prostate Cancer by Upregulating MCL1
S1. Epinephrine inhibits apoptosis by upregulatingMCL1in prostate cancer cells. S2.Epinephrine upregulates MCL1via the ADRB2/PKA pathway S3.C4-2shMCL1 cells with inducible expression of shRNAtargeting MCL1. S4. Effects of chemotherapy drugs on MCL1 expression in prostate cancer cells. S5. The loss of MCL1 expression in cells treated with chemotherapeuticdrugsis restored via ADRB2/PKA signaling.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-5 from β2-adrenoreceptor Signaling Increases Therapy Resistance in Prostate Cancer by Upregulating MCL1
S1. Epinephrine inhibits apoptosis by upregulatingMCL1in prostate cancer cells. S2.Epinephrine upregulates MCL1via the ADRB2/PKA pathway S3.C4-2shMCL1 cells with inducible expression of shRNAtargeting MCL1. S4. Effects of chemotherapy drugs on MCL1 expression in prostate cancer cells. S5. The loss of MCL1 expression in cells treated with chemotherapeuticdrugsis restored via ADRB2/PKA signaling.
- Open Access
- 1 December 2020
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 18 (12) , 1839-1848
β2-adrenoreceptor Signaling Increases Therapy Resistance in Prostate Cancer by Upregulating MCL1
There is accumulating evidence that continuous activation of the sympathetic nervous system due to psychosocial stress increases resistance to therapy and accelerates tumor growth via β2-adrenoreceptor signaling (ADRB2). However, the effector mechanisms appear to be specific to tumor type. Here we show that activation of ADRB2 by epinephrine, increased in response to immobilization stress, delays the loss of MCL1 apoptosis regulator (MCL1) protein expression induced by cytotoxic drugs in prostate cancer cells; and thus, increases resistance of prostate cancer xenografts to cytotoxic therapies. The effect of epinephrine on MCL1 protein depended on protein kinase A (PKA) activity, but was independent from androgen receptor expression. Furthermore, elevated blood epinephrine levels correlated positively with an increased MCL1 protein expression in human prostate biopsies. In summary, we demonstrate that stress triggers an androgen-independent antiapoptotic signaling via the ADRB2/PKA/MCL1 pathway in prostate cancer cells. Implications: Presented results justify clinical studies of ADRB2 blockers as therapeutics and of MCL1 protein expression as potential biomarker predicting efficacy of apoptosis-targeting drugs in prostate cancer.
- 1 December 2020
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 18 (12) , 1839-1848
Open Accessβ2-adrenoreceptor Signaling Increases Therapy Resistance in Prostate Cancer by Upregulating MCL1
There is accumulating evidence that continuous activation of the sympathetic nervous system due to psychosocial stress increases resistance to therapy and accelerates tumor growth via β2-adrenoreceptor signaling (ADRB2). However, the effector mechanisms appear to be specific to tumor type. Here we show that activation of ADRB2 by epinephrine, increased in response to immobilization stress, delays the loss of MCL1 apoptosis regulator (MCL1) protein expression induced by cytotoxic drugs in prostate cancer cells; and thus, increases resistance of prostate cancer xenografts to cytotoxic therapies. The effect of epinephrine on MCL1 protein depended on protein kinase A (PKA) activity, but was independent from androgen receptor expression. Furthermore, elevated blood epinephrine levels correlated positively with an increased MCL1 protein expression in human prostate biopsies. In summary, we demonstrate that stress triggers an androgen-independent antiapoptotic signaling via the ADRB2/PKA/MCL1 pathway in prostate cancer cells. Implications: Presented results justify clinical studies of ADRB2 blockers as therapeutics and of MCL1 protein expression as potential biomarker predicting efficacy of apoptosis-targeting drugs in prostate cancer.
- Open Access
- 1 January 2020
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 2 (1) , vdaa008
Constitutive activation of the EGFR–STAT1 axis increases proliferation of meningioma tumor cells
Meningiomas are the most frequent primary brain tumors of the central nervous system. The standard of treatment is surgery and radiotherapy, but effective pharmacological options are not available yet. The well-characterised genetic background stratifies these tumors in several subgroups, thus increasing diversification. We identified EGFR-STAT1 overexpression and activation as a common identifier of these tumors. We analysed STAT1 overexpression and phosphorylation in 131 meningiomas of different grades and locations by utilising several techniques, including Western blots, qPCR and immunocytochemistry. We also silenced and overexpressed wild-type and mutant forms of the gene to assess its biological function and its network. Results were further validated by drug testing. STAT1 was found widely overexpressed in meningioma but not in the corresponding healthy controls. The protein showed a constitutive phosphorylation not dependent on the JAK/STAT pathway. STAT1 knock-down resulted in a significant reduction of cellular proliferation and deactivation of AKT and ERK1/2. STAT1 is known to be activated by EGFR, so we investigated the tyrosine kinase and found that EGFR was also constitutively phosphorylated in meningioma and was responsible for the aberrant phosphorylation of STAT1. The pharmaceutical inhibition of EGFR caused a significant reduction in cellular proliferation and of overall levels of Cyclin D1, pAKT and pERK1/2. STAT1 EGFR-dependent constitutive phosphorylation is responsible for a positive feedback loop that causes its own overexpression and consequently an increased proliferation of the tumor cells. These findings provide the rationale for further studies aiming to identify effective therapeutic options in meningioma.
- 1 January 2020
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 2 (1) , vdaa008
Open AccessConstitutive activation of the EGFR–STAT1 axis increases proliferation of meningioma tumor cells
Meningiomas are the most frequent primary brain tumors of the central nervous system. The standard of treatment is surgery and radiotherapy, but effective pharmacological options are not available yet. The well-characterised genetic background stratifies these tumors in several subgroups, thus increasing diversification. We identified EGFR-STAT1 overexpression and activation as a common identifier of these tumors. We analysed STAT1 overexpression and phosphorylation in 131 meningiomas of different grades and locations by utilising several techniques, including Western blots, qPCR and immunocytochemistry. We also silenced and overexpressed wild-type and mutant forms of the gene to assess its biological function and its network. Results were further validated by drug testing. STAT1 was found widely overexpressed in meningioma but not in the corresponding healthy controls. The protein showed a constitutive phosphorylation not dependent on the JAK/STAT pathway. STAT1 knock-down resulted in a significant reduction of cellular proliferation and deactivation of AKT and ERK1/2. STAT1 is known to be activated by EGFR, so we investigated the tyrosine kinase and found that EGFR was also constitutively phosphorylated in meningioma and was responsible for the aberrant phosphorylation of STAT1. The pharmaceutical inhibition of EGFR caused a significant reduction in cellular proliferation and of overall levels of Cyclin D1, pAKT and pERK1/2. STAT1 EGFR-dependent constitutive phosphorylation is responsible for a positive feedback loop that causes its own overexpression and consequently an increased proliferation of the tumor cells. These findings provide the rationale for further studies aiming to identify effective therapeutic options in meningioma.